The forecasted treatment success rate for extensively drug-resistant tuberculosis (XDR-TB) patients in Germany shows a distinct downward trend from 2024 onwards, starting at a value of 6 in 2024 and declining each year to reach only 1 by 2028. In 2023, this value had been previously recorded, providing a basis for comparison. This indicates a deteriorating situation with significant year-on-year declines. Over the five-year forecast, the compound annual growth rate (CAGR) reflects a continued negative momentum, underscoring escalating challenges in treatment success for XDR-TB.
Future trends to watch for include developments in new drug regimens or therapies that could potentially stabilize or reverse this downward trend. Additionally, monitoring advancements in diagnostic tools could impact the success rates positively by identifying patients earlier and more accurately. Research focused on understanding drug resistance patterns and patient adherence factors will also be critical in managing the declining treatment success rates.
